Dyadic International stock faces two Nasdaq compliance tests

Published on 10/04/2026 at 15:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dyadic International stock faces a March 24, 2027 Nasdaq deadline after two deficiency notices. Q2 revenue was USD 961,000, while net loss widened 18.4 percent.

DYAI, US26745T1016, Illustration mit AI erstellt.

Dyadic International (ISIN US26745T1016) closed at USD 0.46 on Nasdaq on October 2, 2026, up 6.10 percent, as listing compliance became the stock's central test. According to SEC EDGAR, Dyadic filed a Form 8-K dated September 25, 2026, covering Nasdaq listing deficiencies. The market reaction was positive in the latest completed session, but the regulatory thresholds now define the risk profile.

Two Nasdaq thresholds now matter

StockTitan reports that Dyadic received two notices after 30 consecutive business days below Nasdaq requirements. The first concerns the USD 1.00 minimum bid price, while the second concerns the USD 35.0 million minimum Market Value of Listed Securities.

The company has until March 24, 2027, to meet each test for 10 consecutive business days. At the October 2 closing price of USD 0.46, the stock was 54.0 percent below the USD 1.00 bid-price threshold, making the compliance deadline a concrete valuation and capital-markets issue.

Q2 revenue stayed below USD 1 million

ChoiceStock reported that revenue for the quarter ended June 30, 2026, was USD 961,000, down 0.6 percent from the prior-year quarter. Net loss widened 18.4 percent to USD 2.124 million, and diluted loss per share was USD -0.06.

The figures show the contrast facing Dyadic: the business is advancing protein-production platforms, while quarterly losses remain materially larger than revenue. The company's filings describe applications across life sciences, food and nutrition, and bio-industrial markets, with C1 and Dapibus microbial expression systems supporting recombinant protein and enzyme production.

Consensus target remains USD 3.00

MarketBeat lists a Hold consensus from 2 analysts, with an average, high and low price target of USD 3.00. Using the October 2 price of USD 0.46, that target lies 552.2 percent above the stock price, although the rating mix includes 1 Buy and 1 Sell.

DYAI stays near its yearly low

DYAI closed at USD 0.46 on Nasdaq on October 2, 2026, within its 52-week range of USD 0.34 to USD 1.60, with 142,057 shares traded. The next decisive figures are the USD 1.00 bid-price test, the USD 35.0 million market-value test and the March 24, 2027 compliance date.